
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nephron Extra</journal-id><journal-id journal-id-type="iso-abbrev">Nephron Extra</journal-id><journal-id journal-id-type="publisher-id">NNE</journal-id><journal-title-group><journal-title>Nephron Extra</journal-title></journal-title-group><issn pub-type="ppub">1664-5529</issn><issn pub-type="epub">1664-5529</issn><publisher><publisher-name>S. Karger AG</publisher-name><publisher-loc>Allschwilerstrasse 10, P.O. Box &#x000b7; Postfach &#x000b7; Case postale, CH&#x02013;4009, Basel, Switzerland &#x000b7; Schweiz &#x000b7; Suisse, Phone: +41 61 306 11 11, Fax: +41 61 306 12 34, karger@karger.ch</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23341832</article-id><article-id pub-id-type="pmc">3551384</article-id><article-id pub-id-type="doi">10.1159/000345483</article-id><article-id pub-id-type="publisher-id">nne-0002-0303</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Effects of Carperitide on Contrast-Induced Acute Kidney Injury with a Minimum Volume of Contrast in Chronic Kidney Disease Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Okumura</surname><given-names>Naoki</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hayashi</surname><given-names>Mutsuharu</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Imai</surname><given-names>Enyu</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ishii</surname><given-names>Hideki</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yoshikawa</surname><given-names>Daiji</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yasuda</surname><given-names>Yoshinari</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Goto</surname><given-names>Motomitsu</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Matsuo</surname><given-names>Seiichi</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Oiso</surname><given-names>Yutaka</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Murohara</surname><given-names>Toyoaki</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib></contrib-group><aff id="aff1"><sup>a</sup>Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan</aff><aff id="aff2"><sup>b</sup>Department of CKD Initiatives Internal Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan</aff><aff id="aff3"><sup>c</sup>Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan</aff><aff id="aff4"><sup>d</sup>Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan</aff><author-notes><corresp id="cor1">*Mutsuharu Hayashi, MD, PhD, Department of Cardiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Syouwa-ku, Nagoya 466-8550 (Japan), E-Mail <email>muhayasi@med.nagoya-u.ac.jp</email></corresp></author-notes><pub-date pub-type="collection"><season>Jan-Dec</season><year>2012</year></pub-date><pub-date pub-type="epub"><day>11</day><month>12</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>12</month><year>2012</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>2</volume><issue>1</issue><fpage>303</fpage><lpage>310</lpage><permissions><copyright-statement>Copyright &#x000a9; 2012 by S. Karger AG, Basel</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link>). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on <ext-link ext-link-type="uri" xlink:href="http://www.karger.com">http://www.karger.com</ext-link> and the terms of this license are included in any shared versions.</license-p></license></permissions><abstract><sec><title>Background/Aims</title><p>Although contrast-induced acute kidney injury (CIAKI) is a major complication associated with angiography, the prophylaxis is not well established. Use of a low dose of carperitide for preventing CIAKI remains controversial. We examined the protective effect of carperitide on CIAKI after coronary angiography with a small contrast volume in chronic kidney disease (CKD) patients with coronary artery disease.</p></sec><sec><title>Methods</title><p>We randomly assigned 112 consecutive patients to a carperitide or a control group. The contrast volume was kept under 150 ml. The primary endpoint was the incidence of CIAKI defined by a serum creatinine of &#x02265;25% or a serum creatinine of &#x02265;0.5 mg/dl from baseline within 48 h. The secondary endpoint was a change in renal function at 1 week after the procedure. <bold><italic>Results:</italic></bold> The baseline characteristics and contrast volumes (carperitide group: 67.4 &#x000b1; 38.2 ml vs. control group: 64.8 &#x000b1; 20.5 ml, p = 0.661) were comparable in the two groups. The incidence of CIAKI was similar in the two groups (carperitide group: 8.5% vs. control group: 5.7%, p = 0.564). A multivariate analysis revealed that a hypotension &#x02265;20 mm Hg was a significant predictor of developing CIAKI in the carperitide group (p = 0.015). The incidence of CIAKI in the carperitide group without hypotension was rare, but not significantly different (carperitide group: 2.4% vs. control group: 5.7%, p = 0.432). <bold><italic>Conclusions:</italic></bold> This study indicated that the use of a small contrast volume suppressed the incidence of CIAKI and that carperitide had no prophylactic effect against CIAKI. Our results also revealed the impact of hypotension on the development of CIAKI in the carperitide group.</p></sec></abstract><kwd-group><title>Key Words</title><kwd>Contrast-induced acute kidney injury</kwd><kwd>Carperitide</kwd><kwd>Chronic kidney disease</kwd><kwd>Contrast medium volume</kwd></kwd-group><counts><fig-count count="3"/><table-count count="4"/><ref-count count="20"/><page-count count="8"/></counts></article-meta></front><body><sec id="sec1_1"><title>Introduction</title><p>Contrast-induced acute kidney injury (CIAKI) is one of the major critical complications of coronary angiography (CAG) and/or percutaneous coronary intervention (PCI), and is associated with increased morbidity and mortality [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>].</p><p>The overall incidence of CIAKI in patients with chronic kidney disease (CKD) is extremely higher, at 10&#x02013;25% [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>], than in the general population. Diabetes mellitus, high-dose administration of contrast media, hypotension, anemia, and CKD are reported as the risk factors for CIAKI [<xref ref-type="bibr" rid="B4">4</xref>]. To date, there is no sound evidence supporting the routine use of prophylactic drugs to prevent CIAKI; however, it is potentially possible to diminish the incidence by reducing the volume of contrast media.</p><p>Since recently, technical advances allow performing CAG or PCI with a very small amount of contrast media. The toxicity of contrast media on the kidneys is dose dependent [<xref ref-type="bibr" rid="B5">5</xref>], and a recent report revealed that a volume of contrast medium of &#x02265;155 ml is a risk for CIAKI [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>The pathogenesis of CIAKI is considered to be mainly dependent on renal hypoperfusion and ischemia [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. Carperitide, a member of the natriuretic peptide family with a vasodilating function [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>], was found to have various renoprotective effects, such as improvement of renal plasma flow, reducing the plasma levels of several vasoconstrictors [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. Morikawa et al. [<xref ref-type="bibr" rid="B6">6</xref>] reported that the beneficial effect of low-dose carperitide on renal function is maintained for up to 1 month after contrast medium use. However, another study failed to prove any beneficial effect of carperitide on the incidence of CIAKI [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>The aim of this prospective, randomized, open-label, blinded endpoint (PROBE) study was to determine whether low-dose carperitide has a prophylactic effect against CIAKI under CAG/PCI with a minimum volume of contrast medium in patients with CKD.</p></sec><sec sec-type="materials|methods" id="sec1_2"><title>Materials and Methods</title><sec id="sec2_1"><title>Study Population</title><p>We enrolled a total of 125 consecutive CKD patients undergoing CAG or PCI. CKD was defined as a baseline estimated glomerular filtration rate (eGFR) &#x0003c;60 ml/min/1.73 m<sup>2</sup>, which was calculated by the Modification of Diet in Renal Disease formula modified for Japanese subjects: eGFR = 194 &#x000d7; serum creatinine<sup>&#x02212;1.094</sup> &#x000d7; age<sup>&#x02212;0.287</sup> &#x000d7; 0.739 (if female) [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. The exclusion criteria included hypersensitivity to contrast media or carperitide; a baseline systolic blood pressure &#x0003c;110 mm Hg; the use of vasopressors before the procedure; current hemodialysis; planned post-contrast medium dialysis; major surgery or contrast medium use within 10 days before the study; acute coronary syndrome; multiple myeloma; parenteral use of diuretics, and the administration of N-acetylcysteine, metformin, sodium bicarbonate, fenoldopam, mannitol, or nonsteroidal anti-inflammatory drugs (NSAIDs). We excluded the patients who required cardiac mechanical support (intra-aortic balloon pumping or percutaneous cardiopulmonary support) during the procedure.</p><p>We calculated the sample size assuming a CIAKI rate of 20% in the control group based on the incidence rate previously reported in CKD patients undergoing CAG [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Also, we assumed that the incidence of CIAKI decreases to almost one seventh through the administration of carperitide [<xref ref-type="bibr" rid="B13">13</xref>]. Based on these assumptions, we calculated that 57 patients were needed in each treatment group to detect a statistically significant difference between treatment groups using the log-rank test with &#x003b1; = 0.05 (two-sided) and 1 &#x02013; &#x003b2; = 0.80.</p><p>The study protocol and chart reviews were approved by our institutional ethics committee. Written informed consent was given by all patients prior to the procedure.</p></sec><sec id="sec2_2"><title>Study Protocol</title><p>Patients were randomly assigned to receive either carperitide (Daiichi-Sankyo Co., Ltd., Tokyo, Japan) in addition to intravenous hydration with 1.0 ml/kg/h of saline (carperitide group) or only hydration with saline (control group) for 12&#x02013;18 h before and for 6 h after contrast administration. Carperitide was dissolved in a 5% carbohydrate solution and adjusted to 0.025 &#x003bc;g/kg/min. Iohexol (Omnipaque 350; Daiichi-Sankyo Co., Ltd.), a nonionic, low-osmolality contrast medium, was used in all patients. When the systolic blood pressure decreased below 90 mm Hg, carperitide was reduced to half a dose. When we recognized a consistent decrease in the systolic blood pressure (to &#x0003c;90 mm Hg) or when the patients&#x02019; symptoms were dependent on blood pressure oscillations, we excluded the patients from this study.</p><p>The primary endpoint was the incidence of CIAKI defined as a 25% increase in creatinine or an increase in creatinine by 0.5 mg/dl from baseline at the maximum value obtained within 48 h after the procedure [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. The serum creatinine and cystatin C levels were measured at 12&#x02013;24 h before the procedure, and at 24&#x02013;48 h and 1 week after the procedure. The secondary endpoint was the changes in the serum creatinine and serum cystatin C concentrations at 1 week after procedure.</p></sec><sec id="sec2_3"><title>Statistical Analysis</title><p>The STATA/SE11 software program was used for all statistical analyses. We tested the distribution of continuous variables for normality with a one-sample Kolmogorov-Smirnov test. Continuous variables were presented as the means (standard deviations), and differences between the two groups were evaluated by Student's unpaired t test or the Wilcoxon test if the distribution was abnormal. Comparisons across the two groups were performed by the &#x003c7;<sup>2</sup> test. We used a logistic regression analysis for the multivariable analysis. After initial therapy, the statistical analysis was based on an intention-to-treat analysis.</p></sec></sec><sec sec-type="results" id="sec1_3"><title>Results</title><p>Seven patients (2 refused to participate in the study, 5 did not meet the inclusion criteria) did not participate in this study. Two patients with symptomatic hypotension were excluded because of their intolerance to carperitide. After CAG, 4 patients (3 who received a dose of contrast medium &#x0003e;150 ml, and 1 who required intra-aortic balloon pumping) were excluded. Therefore, 112 patients were eligible for this study (carperitide group: n = 59, placebo group: n = 53) (fig. <xref ref-type="fig" rid="F1">1</xref>).</p><p>Table <xref ref-type="table" rid="T1">1</xref> shows the baseline clinical characteristics of the enrolled patients. There were no significant differences between the two groups. Also, the patients&#x02019; baseline renal function was comparable.</p><p>The volume of contrast medium used (table <xref ref-type="table" rid="T2">2</xref>) was similar in both groups (carperitide group: 67.4 &#x000b1; 38.2 ml vs. control group: 64.8 &#x000b1; 20.5 ml, p = 0.661). When compared with the control group, carperitide infusion produced a significant decrease in the systolic blood pressure at 12 h [&#x02212;3.5 (&#x02212;7 to 2) vs. &#x02212;14 (&#x02212;20 to &#x02212;8.5) mm Hg, p &#x0003c; 0.001]. The incidence of a critical systolic blood pressure reduction, defined as a systolic blood pressure reduction &#x02264;&#x02212;20 mm Hg, was significantly higher in the carperitide group than in the control group (p &#x0003c; 0.001).</p><p>There were no significant differences for the primary outcome of the development of CIAKI between the groups (carperitide group: 8.5% vs. control group: 5.7%, p = 0.564) (fig. <xref ref-type="fig" rid="F2">2</xref>). Of importance, only an increase in serum creatinine &#x0003e;25% occurred as an indicator of CIAKI, and there were no patients who developed CIAKI strictly defined as an increase in serum creatinine of &#x02265;0.5 mg/dl.</p><p>According to the secondary endpoint, the adverse effects of contrast medium on renal function were also similar in both groups. Table <xref ref-type="table" rid="T3">3</xref> shows the changes in renal functional markers. In the carperitide group, there was a significant deterioration in the serum creatinine, eGFR, and serum cystatin C levels compared to the control group at 24&#x02013;48 h after the administration of the contrast medium (p = 0.002, 0.006, 0.001, respectively). In contrast, the serum creatinine level showed a tendency to decrease in the carperitide group at 1 week after contrast medium use, but not significantly so.</p><p>A univariate analysis of the incidence of CIAKI in the carperitide group revealed that hypotension defined as a severe systolic blood pressure reduction by &#x02264;&#x02212;20 mm Hg was a significant predictor [odds ratio (OR) 15.6 (1.58&#x02013;154.28), p = 0.019] (table <xref ref-type="table" rid="T4">4</xref>). When all variants of the patients&#x02019; age, diabetes mellitus status, angiotensin II receptor blocker (ARB) and statin use, and hypotension detected by the univariate analysis were included in the multivariate model, hypotension was an independent predictor of the development of CIAKI in the carperitide group [OR 31.87 (1.93&#x02013;525.58), p = 0.015]. Furthermore, all patients who developed CIAKI in the carperitide group and 75% of the patients who developed CIAKI in both groups were treated with calcium channel blockers. Although the incidence of CIAKI in the carperitide group without hypotension was low, it was comparable to that in the placebo group (2.4 vs. 5.7%, respectively, p = 0.432) (fig. <xref ref-type="fig" rid="F3">3</xref>).</p></sec><sec sec-type="discussion" id="sec1_4"><title>Discussion</title><p>The pathogenesis of CIAKI is considered to be linked to the cytotoxic effects of contrast media and renal vasoconstriction. In the present study, we showed that CAG with low-dose contrast medium decreased the incidence of CIAKI by about 50% compared to previous reports and none of our CKD patients with CAG developed strictly defined CIAKI (&#x02265;0.5 mg/dl serum creatinine), which is reported to be a more sensitive definition for mortality and morbidity in patients with CIAKI [<xref ref-type="bibr" rid="B17">17</xref>]. Carperitide, a renal-specific vasodilator, has been reported to have preventive effects on contrast-induced renal injury because of improvement of renal perfusion [<xref ref-type="bibr" rid="B18">18</xref>]. Contrary to the previously reported protective effects of carperitide, our current results did not demonstrate the advantages for CIAKI. A sub-analysis of CIAKI in the carperitide group showed an impact of hypotension, which was suggested to disturb the renoprotective effects of carperitide. Also, our sub-analysis revealed that combination therapy using calcium channel antagonists with carperitide could potentially predict the development of CIAKI. Glomerular hypoperfusion induced by systemic arterial pressure reduction due to treatment with dual vasodilators is suggested to result in glomerular dysfunction within 48 h after contrast medium use.</p><p>Mehran et al. [<xref ref-type="bibr" rid="B19">19</xref>] reported the utility of a CIAKI risk stratification score based on 8 available variables, and we can improve the procedure-related factors including the contrast volume. The present study indicates that decreasing the volume of contrast medium is indispensable for the prophylaxis of CIAKI, especially in CKD patients. When the contrast volume is suppressed to &#x0003c;100 ml, a critical blood pressure reduction exerts adverse effects on the development of CIAKI. The results of our sub-analysis emphasize the need for avoiding excessive use of vasodilators in order to maintain the renal circulation. As the incidence of hypotension was higher in the carperitide group, carperitide use should be avoided when the contrast medium volume is suppressed. The determination of an adaptable dose of carperitide, without hypotension, is essential for an effective and safe use of carperitide in patients with CAG/PCI.</p><sec id="sec2_4"><title>Study Limitations</title><p>First, the diagnosis of CIAKI depended on the peak value of the serum creatinine concentration within 48 h after contrast medium use [<xref ref-type="bibr" rid="B20">20</xref>]. However, because of our institutional limitations concerning the frequency and timing of blood collection, the degree of the elevation of creatinine might have been underestimated. Second, this study was a single-center study and was not blinded. Third, the incidence of CIAKI was lower than predicted under procedures using a small amount of contrast medium.</p></sec></sec><sec id="sec1_5"><title>Disclosure Statement</title><p>The authors declare that they have no conflicts of interest.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors are indebted to all technicians, nurses, and doctors in the catheterization laboratories, the intensive care unit, and on the wards for their ongoing support.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>EM</given-names></name><name><surname>Viscoli</surname><given-names>CM</given-names></name><name><surname>Horwitz</surname><given-names>RI</given-names></name></person-group><article-title>The effect of acute renal failure on mortality. A cohort analysis</article-title><source>JAMA</source><year>1996</year><volume>275</volume><fpage>1489</fpage><lpage>1494</lpage><pub-id pub-id-type="pmid">8622223</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weisbord</surname><given-names>SD</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Stone</surname><given-names>RA</given-names></name><name><surname>Kip</surname><given-names>KE</given-names></name><name><surname>Fine</surname><given-names>MJ</given-names></name><name><surname>Saul</surname><given-names>MI</given-names></name><name><surname>Palevsky</surname><given-names>PM</given-names></name></person-group><article-title>Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography</article-title><source>J Am Soc Nephrol</source><year>2006</year><volume>17</volume><fpage>2871</fpage><lpage>2877</lpage><pub-id pub-id-type="pmid">16928802</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aspelin</surname><given-names>P</given-names></name><name><surname>Aubry</surname><given-names>P</given-names></name><name><surname>Fransson</surname><given-names>SG</given-names></name><name><surname>Strasser</surname><given-names>R</given-names></name><name><surname>Willenbrock</surname><given-names>R</given-names></name><name><surname>Berg</surname><given-names>KJ</given-names></name></person-group><article-title>Nephrotoxic effects in high-risk patients undergoing angiography</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>491</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">12571256</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCullough</surname><given-names>PA</given-names></name></person-group><article-title>Contrast-induced acute kidney injury</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>51</volume><fpage>1419</fpage><lpage>1428</lpage><pub-id pub-id-type="pmid">18402894</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeder</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>M</given-names></name><name><surname>Fehr</surname><given-names>T</given-names></name><name><surname>Rickli</surname><given-names>H</given-names></name></person-group><article-title>Contrast nephropathy: review focusing on prevention</article-title><source>J Am Coll Cardiol</source><year>2004</year><volume>44</volume><fpage>1763</fpage><lpage>1771</lpage><pub-id pub-id-type="pmid">15519005</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morikawa</surname><given-names>S</given-names></name><name><surname>Sone</surname><given-names>T</given-names></name><name><surname>Tsuboi</surname><given-names>H</given-names></name><name><surname>Mukawa</surname><given-names>H</given-names></name><name><surname>Morishima</surname><given-names>I</given-names></name><name><surname>Uesugi</surname><given-names>M</given-names></name><name><surname>Morita</surname><given-names>Y</given-names></name><name><surname>Numaguchi</surname><given-names>Y</given-names></name><name><surname>Okumura</surname><given-names>K</given-names></name><name><surname>Murohara</surname><given-names>T</given-names></name></person-group><article-title>Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide</article-title><source>J Am Coll Cardiol</source><year>2009</year><volume>53</volume><fpage>1040</fpage><lpage>1046</lpage><pub-id pub-id-type="pmid">19298916</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brezis</surname><given-names>M</given-names></name><name><surname>Rosen</surname><given-names>S</given-names></name></person-group><article-title>Hypoxia of the renal medulla &#x02013; its implications for disease</article-title><source>N Engl J Med</source><year>1995</year><volume>332</volume><fpage>647</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">7845430</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>CA</given-names></name><name><surname>Manning</surname><given-names>HL</given-names></name></person-group><article-title>Prevention of acute renal failure in the critically ill</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>165</volume><fpage>320</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">11818313</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kangawa</surname><given-names>K</given-names></name><name><surname>Matsuo</surname><given-names>H</given-names></name></person-group><article-title>Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP)</article-title><source>Biochem Biophys Res Commun</source><year>1984</year><volume>118</volume><fpage>131</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">6230082</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proctor</surname><given-names>KG</given-names></name><name><surname>Bealer</surname><given-names>SL</given-names></name></person-group><article-title>Selective antagonism of hormone-induced vasoconstriction by synthetic atrial natriuretic factor in the rat microcirculation</article-title><source>Circ Res</source><year>1987</year><volume>61</volume><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">2955950</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandok</surname><given-names>EK</given-names></name><name><surname>Lerman</surname><given-names>A</given-names></name><name><surname>Stingo</surname><given-names>AJ</given-names></name><name><surname>Perrella</surname><given-names>MA</given-names></name><name><surname>Gloviczki</surname><given-names>P</given-names></name><name><surname>Burnett</surname><given-names>JC</given-names><suffix>Jr</suffix></name></person-group><article-title>Endothelin in a model of acute ischemic renal dysfunction: modulating action of atrial natriuretic factor</article-title><source>J Am Soc Nephrol</source><year>1992</year><volume>3</volume><fpage>196</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">1391720</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emori</surname><given-names>T</given-names></name><name><surname>Hirata</surname><given-names>Y</given-names></name><name><surname>Imai</surname><given-names>T</given-names></name><name><surname>Eguchi</surname><given-names>S</given-names></name><name><surname>Kanno</surname><given-names>K</given-names></name><name><surname>Marumo</surname><given-names>F</given-names></name></person-group><article-title>Cellular mechanism of natriuretic peptides-induced inhibition of endothelin-1 biosynthesis in rat endothelial cells</article-title><source>Endocrinology</source><year>1993</year><volume>133</volume><fpage>2474</fpage><lpage>2480</lpage><pub-id pub-id-type="pmid">8243267</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wada</surname><given-names>A</given-names></name><name><surname>Tsutamoto</surname><given-names>T</given-names></name><name><surname>Matsuda</surname><given-names>Y</given-names></name><name><surname>Kinoshita</surname><given-names>M</given-names></name></person-group><article-title>Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors</article-title><source>Circulation</source><year>1994</year><volume>89</volume><fpage>2232</fpage><lpage>2240</lpage><pub-id pub-id-type="pmid">7910118</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurnik</surname><given-names>BR</given-names></name><name><surname>Allgren</surname><given-names>RL</given-names></name><name><surname>Genter</surname><given-names>FC</given-names></name><name><surname>Solomon</surname><given-names>RJ</given-names></name><name><surname>Bates</surname><given-names>ER</given-names></name><name><surname>Weisberg</surname><given-names>LS</given-names></name></person-group><article-title>Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy</article-title><source>Am J Kidney Dis</source><year>1998</year><volume>31</volume><fpage>674</fpage><lpage>680</lpage><pub-id pub-id-type="pmid">9531185</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>E</given-names></name><name><surname>Horio</surname><given-names>M</given-names></name><name><surname>Nitta</surname><given-names>K</given-names></name><name><surname>Yamagata</surname><given-names>K</given-names></name><name><surname>Iseki</surname><given-names>K</given-names></name><name><surname>Hara</surname><given-names>S</given-names></name><name><surname>Ura</surname><given-names>N</given-names></name><name><surname>Kiyohara</surname><given-names>Y</given-names></name><name><surname>Hirakata</surname><given-names>H</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Moriyama</surname><given-names>T</given-names></name><name><surname>Ando</surname><given-names>Y</given-names></name><name><surname>Inaguma</surname><given-names>D</given-names></name><name><surname>Narita</surname><given-names>I</given-names></name><name><surname>Iso</surname><given-names>H</given-names></name><name><surname>Wakai</surname><given-names>K</given-names></name><name><surname>Yasuda</surname><given-names>Y</given-names></name><name><surname>Tsukamoto</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Makino</surname><given-names>H</given-names></name><name><surname>Hishida</surname><given-names>A</given-names></name><name><surname>Matsuo</surname><given-names>S</given-names></name></person-group><article-title>Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease</article-title><source>Clin Exp Nephrol</source><year>2007</year><volume>11</volume><fpage>41</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">17384997</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuo</surname><given-names>S</given-names></name><name><surname>Imai</surname><given-names>E</given-names></name><name><surname>Horio</surname><given-names>M</given-names></name><name><surname>Yasuda</surname><given-names>Y</given-names></name><name><surname>Tomita</surname><given-names>K</given-names></name><name><surname>Nitta</surname><given-names>K</given-names></name><name><surname>Yamagata</surname><given-names>K</given-names></name><name><surname>Tomino</surname><given-names>Y</given-names></name><name><surname>Yokoyama</surname><given-names>H</given-names></name><name><surname>Hishida</surname><given-names>A</given-names></name></person-group><article-title>Revised equations for estimated GFR from serum creatinine in Japan</article-title><source>Am J Kidney Dis</source><year>2009</year><volume>53</volume><fpage>982</fpage><lpage>992</lpage><pub-id pub-id-type="pmid">19339088</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrario</surname><given-names>F</given-names></name><name><surname>Barone</surname><given-names>MT</given-names></name><name><surname>Landoni</surname><given-names>G</given-names></name><name><surname>Genderini</surname><given-names>A</given-names></name><name><surname>Heidemperger</surname><given-names>M</given-names></name><name><surname>Trezzi</surname><given-names>M</given-names></name><name><surname>Piccaluga</surname><given-names>E</given-names></name><name><surname>Danna</surname><given-names>P</given-names></name><name><surname>Scorza</surname><given-names>D</given-names></name></person-group><article-title>Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy &#x02013; a randomized controlled study</article-title><source>Nephrol Dial Transplant</source><year>2009</year><volume>24</volume><fpage>3103</fpage><lpage>3107</lpage><pub-id pub-id-type="pmid">19549691</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valsson</surname><given-names>F</given-names></name><name><surname>Ricksten</surname><given-names>SE</given-names></name><name><surname>Hedner</surname><given-names>T</given-names></name><name><surname>Lundin</surname><given-names>S</given-names></name></person-group><article-title>Effects of atrial natriuretic peptide on acute renal impairment in patients with heart failure after cardiac surgery</article-title><source>Intensive Care Med</source><year>1996</year><volume>22</volume><fpage>230</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">8727437</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehran</surname><given-names>R</given-names></name><name><surname>Aymong</surname><given-names>ED</given-names></name><name><surname>Nikolsky</surname><given-names>E</given-names></name><name><surname>Lasic</surname><given-names>Z</given-names></name><name><surname>Iakovou</surname><given-names>I</given-names></name><name><surname>Fahy</surname><given-names>M</given-names></name><name><surname>Mintz</surname><given-names>GS</given-names></name><name><surname>Lansky</surname><given-names>AJ</given-names></name><name><surname>Moses</surname><given-names>JW</given-names></name><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Leon</surname><given-names>MB</given-names></name><name><surname>Dangas</surname><given-names>G</given-names></name></person-group><article-title>A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation</article-title><source>J Am Coll Cardiol</source><year>2004</year><volume>44</volume><fpage>1393</fpage><lpage>1399</lpage><pub-id pub-id-type="pmid">15464318</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrew</surname><given-names>E</given-names></name><name><surname>Berg</surname><given-names>KJ</given-names></name></person-group><article-title>Nephrotoxic effects of X-ray contrast media</article-title><source>J Toxicol Clin Toxicol</source><year>2004</year><volume>42</volume><fpage>325</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">15362604</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Randomization and clinical diagnoses of all patients. IABP = Intra-aortic balloon pumping.</p></caption><graphic xlink:href="nne-0002-0303-g01"/></fig><fig id="F2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>The incidence of CIAKI was a little higher in the carperitide group than in the control group, but the difference was not statistically significant.</p></caption><graphic xlink:href="nne-0002-0303-g02"/></fig><fig id="F3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>The incidence of CIAKI was higher in the control group than in the carperitide group without severe blood pressure reduction, but the difference was not statistically significant.</p></caption><graphic xlink:href="nne-0002-0303-g03"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of study patients</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Carperitide group (n = 59)</th><th align="left" rowspan="1" colspan="1">Control group (n = 53)</th><th align="left" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr valign="top"><td align="left" rowspan="1" colspan="1">Age, years</td><td align="char" char="." rowspan="1" colspan="1">74 (8.9)</td><td align="char" char="." rowspan="1" colspan="1">73.0 (6.3)</td><td align="left" rowspan="1" colspan="1">0.566</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Male, %</td><td align="char" char="." rowspan="1" colspan="1">68</td><td align="char" char="." rowspan="1" colspan="1">83</td><td align="left" rowspan="1" colspan="1">0.080</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Body mass index</td><td align="char" char="." rowspan="1" colspan="1">23.9 (3.1)</td><td align="char" char="." rowspan="1" colspan="1">23.6 (3.4)</td><td align="left" rowspan="1" colspan="1">0.682</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Systolic blood pressure, mm Hg</td><td align="char" char="." rowspan="1" colspan="1">129.9 (17.6)</td><td align="char" char="." rowspan="1" colspan="1">135.1 (20.7)</td><td align="left" rowspan="1" colspan="1">0.152</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Hypertension, %</td><td align="char" char="." rowspan="1" colspan="1">83</td><td align="char" char="." rowspan="1" colspan="1">77</td><td align="left" rowspan="1" colspan="1">0.449</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Diabetes mellitus, %</td><td align="char" char="." rowspan="1" colspan="1">59</td><td align="char" char="." rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">0.137</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">History of myocardial infarction, %</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">0.981</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">History of congestive heart failure, %</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">0.859</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Medication, %</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;ACE inhibitors</td><td align="char" char="." rowspan="1" colspan="1">18</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">0.158</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;ARBs</td><td align="char" char="." rowspan="1" colspan="1">56</td><td align="char" char="." rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">0.513</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Calcium channel blockers</td><td align="char" char="." rowspan="1" colspan="1">52</td><td align="char" char="." rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">0.306</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Diuretics</td><td align="char" char="." rowspan="1" colspan="1">34</td><td align="char" char="." rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">0.718</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Statins</td><td align="char" char="." rowspan="1" colspan="1">68</td><td align="char" char="." rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">0.721</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">LVEF, %</td><td align="char" char="." rowspan="1" colspan="1">62.6 (12.4)</td><td align="char" char="." rowspan="1" colspan="1">59.0 (15.7)</td><td align="left" rowspan="1" colspan="1">0.198</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Current smoker, %</td><td align="char" char="." rowspan="1" colspan="1">24</td><td align="char" char="." rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">0.121</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as means (SD) for continuous variables, and percentages for categorical variables. ACE = Angiotensin-converting enzyme; LVEF = left ventricular ejection fraction.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Contrast volume and c hanges in blood pressure of study patients</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Carperitide group (n = 59)</th><th align="left" rowspan="1" colspan="1">Control group (n = 53)</th><th align="left" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr valign="top"><td align="left" rowspan="1" colspan="1">Contrast medium volume, ml</td><td align="left" rowspan="1" colspan="1">67.4 (38.2)</td><td align="left" rowspan="1" colspan="1">64.8 (20.5)</td><td align="left" rowspan="1" colspan="1">0.661</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Change in systolic blood pressure, mm Hg</td><td align="left" rowspan="1" colspan="1">&#x02212;14 (&#x02212;20 to &#x02212;8.5)</td><td align="left" rowspan="1" colspan="1">&#x02212;3.5 (&#x02212;7 to &#x02212;2)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Incidence of hypotension<sup>1</sup>, %</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as means (SD) or medians (interquartile ranges) for continuous variables and percentages for categorical variables.</p></fn></table-wrap-foot><table-wrap-foot><fn id="T2F1"><label>1</label><p>Incidence of hypotension is defined as a systolic blood pressure reduction &#x02264;&#x02212;20 mm Hg from baseline.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Changes from baseline in serum creatinine, eGFR, and serum cystatin C</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Carperitide group (n = 59)</th><th align="left" rowspan="1" colspan="1">Control group (n = 53)</th><th align="left" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr valign="top"><td align="left" rowspan="1" colspan="1">Serum creatinine, mg/dl</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="left" rowspan="1" colspan="1">1.16 (0.99&#x02013;1.27)</td><td align="left" rowspan="1" colspan="1">1.18 (1&#x02013;1.44)</td><td align="left" rowspan="1" colspan="1">0.493</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Change within 48 h</td><td align="left" rowspan="1" colspan="1">0.05 (&#x02212;0.03 to 0.13)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.03 (&#x02212;0.08 to 0.07)</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Change at 1 week</td><td align="left" rowspan="1" colspan="1">&#x02212;0.03 (&#x02212;0.09 to 0.04)</td><td align="left" rowspan="1" colspan="1">0.01 (&#x02212;0.06 to 0.07)</td><td align="left" rowspan="1" colspan="1">0.054</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">eGFR, ml/min/1.73 m<sup>2</sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="left" rowspan="1" colspan="1">44.4 (9.2)</td><td align="left" rowspan="1" colspan="1">45.4 (10.4)</td><td align="left" rowspan="1" colspan="1">0.574</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Change within 48 h</td><td align="left" rowspan="1" colspan="1">&#x02212;2.0 (6.1)</td><td align="left" rowspan="1" colspan="1">0.8 (4.3)</td><td align="left" rowspan="1" colspan="1">0.006</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Change at 1 week</td><td align="left" rowspan="1" colspan="1">0.9 (5.6)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.4 (4.3)</td><td align="left" rowspan="1" colspan="1">0.169</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Serum cystatin C, mg/l</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="left" rowspan="1" colspan="1">1.47 (1.26-1.64)</td><td align="left" rowspan="1" colspan="1">1.36 (1.23&#x02013;1.7)</td><td align="left" rowspan="1" colspan="1">0.630</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Change within 48 h</td><td align="left" rowspan="1" colspan="1">0.09 (&#x02212;0.01 to 0.18)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.03 (&#x02212;0.11 to 0.07)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">&#x02003;Change at 1 week</td><td align="left" rowspan="1" colspan="1">&#x02212;0.01 (&#x02212;0.08 to 0.04)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.01 (&#x02212;0.1 to 0.05)</td><td align="left" rowspan="1" colspan="1">0.242</td></tr></tbody></table><table-wrap-foot><fn><p>Data are presented as means (SD) or medians (interquartile ranges).</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Univariate and multivariate analysis for CI AKI in the carperitide group
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="1" colspan="1"/><th align="left" colspan="2" rowspan="1">CIAKI, %<hr/></th><th align="left" colspan="2" rowspan="1">Univariate analysis<hr/></th><th align="left" colspan="2" rowspan="1">Multivariate analysis<hr/></th></tr><tr valign="top"><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">(+)</th><th align="left" rowspan="1" colspan="1">(&#x02013;)</th><th align="left" rowspan="1" colspan="1">OR 95% CI</th><th align="left" rowspan="1" colspan="1">p value</th><th align="left" rowspan="1" colspan="1">OR 95% CI</th><th align="left" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr valign="top"><td align="left" rowspan="1" colspan="1">Age &#x0003e;70 years</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1">1.14 (0.12&#x02013;11.21)</td><td align="left" rowspan="1" colspan="1">0.909</td><td align="left" rowspan="1" colspan="1">1.08 (0.1&#x02013;33.16)</td><td align="left" rowspan="1" colspan="1">0.960</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">2.97 (0.31&#x02013;28.35)</td><td align="left" rowspan="1" colspan="1">0.325</td><td align="left" rowspan="1" colspan="1">10.49 (0.40&#x02013;275.51)</td><td align="left" rowspan="1" colspan="1">0.159</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Dyslipidemia</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">1.83 (0.19&#x02013;17.71)</td><td align="left" rowspan="1" colspan="1">0.599</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">82</td><td align="left" rowspan="1" colspan="1">0.91 (0.09&#x02013;9.03)</td><td align="left" rowspan="1" colspan="1">0.940</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">ARBs</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">59</td><td align="left" rowspan="1" colspan="1">0.17 (0.02&#x02013;1.64)</td><td align="left" rowspan="1" colspan="1">0.126</td><td align="left" rowspan="1" colspan="1">0.78 (0&#x02013;1.61)</td><td align="left" rowspan="1" colspan="1">0.099</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Statins</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">0.63 (0.10&#x02013;4.15)</td><td align="left" rowspan="1" colspan="1">0.630</td><td align="left" rowspan="1" colspan="1">0.22 (0.13&#x02013;3.35)</td><td align="left" rowspan="1" colspan="1">0.274</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Incidence of hypotension<xref ref-type="table-fn" rid="T4F1"><sup>1</sup></xref></td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">15.6 (1.58&#x02013;154.28)</td><td align="left" rowspan="1" colspan="1">0.019</td><td align="left" rowspan="1" colspan="1">31.87 (1.93&#x02013;525.58)</td><td align="left" rowspan="1" colspan="1">0.015</td></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">LVEF(&#x02265;40%)</td><td align="left" rowspan="1" colspan="1">80</td><td align="left" rowspan="1" colspan="1">93</td><td align="left" rowspan="1" colspan="1">0.32 (0.29&#x02013;3.59)</td><td align="left" rowspan="1" colspan="1">0.333</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">Contrast medium &#x0003e;65 ml</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">1.23 (0.19&#x02013;8.00)</td><td align="left" rowspan="1" colspan="1">0.830</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr valign="top"><td align="left" rowspan="1" colspan="1">History of myocardial infarction</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">1.44 (0.14&#x02013;14.57)</td><td align="left" rowspan="1" colspan="1">0.758</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>LVEF = Left ventricular ejection fraction; CI = confidence interval.</p></fn></table-wrap-foot><table-wrap-foot><fn id="T4F1"><label>1</label><p>Incidence of hypotension is defined as a systolic blood pressure reduction &#x02264;&#x02212;20 mm Hg from baseline.</p></fn></table-wrap-foot></table-wrap></floats-group></article>